



PRESS RELEASE

MOBERG PHARMA'S NOMINATION COMMITTEE APPOINTED

STOCKHOLM, November 10th, 2017 - In accordance with the resolution of the Annual General Meeting on May 18, 2017, the Chairman of the Board has contacted the company's three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company's three largest shareholders or group of shareholders have wished to appoint such representative, the fourth largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of four members, in accordance with the resolution of the Annual General Meeting on May 18.

Moberg Pharma's Nomination Committee ahead of the 2018 Annual General Meeting comprises:

- Thomas Eklund, Chairman of the Board
- Gillis Cullin, appointed by Östersjöstiftelsen
- Fredrik Persson, appointed by Zimbrine Holding
- Anders Rodebjer, appointed by Wolco Invest

Together, the Nomination Committee represents 25.3 percent of the shares in Moberg Pharma as of September 30, 2017.

The Nomination Committee shall submit proposals for resolution by the 2018 Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors' fees and the election of auditors.

The 2018 Annual General Meeting will be held in Stockholm on May 15.

Shareholders wishing to submit proposals to Moberg Pharma's Nomination Committee can do so by e-mail to info@mobergpharma.se by 31 December 2017.

For additional information, please contact:

Peter Wolpert, CEO, Phone: +1 908 432 22 03 (US), +46 707 35 71 35 (SE), E-mail: peter.wolpert@mobergpharma.se

Anna Ljung, CFO, Phone: +46 707 66 60 30, E-mail: anna.ljung@mobergpharma.se

About this information

This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. CET on November 10th, 2017.

About Moberg Pharma, www.mobergpharma.com

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company's portfolio includes the OTC brands Kerasal[®], Kerasal Nail[®], Balmex[®], New Skin[®], Dermoplast[®] and Domeboro[®]. Kerasal Nail[®] (Emtrix[®], Zanmira[®] or Nalox[™] in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).